Instil Bio Advances in NSCLC Trials with AXN-2510 Antibody

Instil Bio shares are trading higher after the company announced progress in the Phase 2 trial of their PD-L1xVEGF bispecific antibody AXN-2510 in China. The positive momentum is further supported by H.C. Wainwright maintaining a 'Buy' rating with a revised price target of $105.